Relief of anxiety disorder may be achieved with kava

The department of psychiatry at the University of Melbourne lead the first completed randomised controlled trial of kava for GAD, using an extract of peeled rootstock in pills providing a 120mg dose daily, taken for three weeks.

The study of 75 patients with GAD found 26% of those taking kava tablets had symptom remission compared to 6% of those taking placebo, although genetic differences influenced response.

The trial was funded by the NHMRC and kava product manufacturer Integria Healthcare